Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger B Cohen

Showing results (121-130 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Investigational New Drugs|May 22, 2018
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumorsA Craig Lockhart, Todd M Bauer, Charu Aggarwal, et al.
The Oncologist|March 6, 2019
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced CancerAiwu Ruth He, Roger B Cohen, Crystal S Denlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Head & Neck|March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinibLaura Vidal, Ming S Tsao, Gregory R Pond, et al.
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2010
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumorsE Claire Dees, Jeffrey R Infante, Roger B Cohen, et al.
Clinical Genetics|September 12, 2022
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthoodKara N Maxwell, Vishal Patel, Kevin T Nead, et al.
Cancers|May 28, 2022
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E Bauman, Ricklie Julian, Nabil F Saba, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Pageof 21

Showing results (121-130 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Investigational New Drugs|May 22, 2018
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumorsA Craig Lockhart, Todd M Bauer, Charu Aggarwal, et al.
The Oncologist|March 6, 2019
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced CancerAiwu Ruth He, Roger B Cohen, Crystal S Denlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Head & Neck|March 25, 2009
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinibLaura Vidal, Ming S Tsao, Gregory R Pond, et al.
JCO Oncology Practice|May 27, 2020
Management of Lung Cancer During the COVID-19 PandemicAditi P Singh, Abigail T Berman, Melina E Marmarelis, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2010
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumorsE Claire Dees, Jeffrey R Infante, Roger B Cohen, et al.
Clinical Genetics|September 12, 2022
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthoodKara N Maxwell, Vishal Patel, Kevin T Nead, et al.
Cancers|May 28, 2022
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E Bauman, Ricklie Julian, Nabil F Saba, et al.
Cancer|October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs dataJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Pageof 21